Limbic-predominant age-related TDP-43 encephalopathy explained

LATE is a term that describes a prevalent condition with impaired memory and thinking in advanced age, often culminating in the dementia clinical syndrome.[1] In other words, the symptoms of LATE are similar to those of Alzheimer's disease.  

The acronym LATE stands for Limbic-predominant Age-related TDP-43 Encephalopathy: “limbic” is related to the brain areas first involved, “age-related” and the name “LATE” itself refer to the onset of disease usually in persons aged 80 or older,  “TDP-43” indicates the aberrant mis-folded protein (or proteinopathy) deposits in the brain that characterize LATE, and “encephalopathy” means illness of brain.

At present LATE can only be diagnosed with certainty at autopsy. The terminology used to refer to the brain changes identified in autopsy-confirmed LATE is: LATE neuropathologic change (LATE-NC). The diagnosis of LATE-NC at autopsy requires detection of pathologic TDP-43 protein deposits in the brain, especially in the amygdala and hippocampus.

LATE is a very common condition: autopsy studies around the world indicate that LATE is present in the brains of about one-third of people over 85.[2] [3] LATE typically affects persons older than 75 years of age (with some exceptions; please see below) and becomes increasingly prevalent every year in advanced old age. This is in contrast to Alzheimer's disease pathology, which tends to level off and perhaps decrease in prevalence among persons beyond age 85 years. LATE is often comorbid with (i.e., occurs in the same brain as) other pathologic changes that are associated with dementia, such as Alzheimer's disease and cerebrovascular disease(s).[4] [5] [6]

LATE has a large impact on public health. Clinical-pathologic correlation studies have established that the presence of LATE-NC is associated with impairments in memory and thinking. In older persons whose brains lack Alzheimer's disease-type amyloid plaques and neurofibrillary tangles, the presence of LATE-NC at autopsy is associated with a relatively slow cognitive decline (in comparison with Alzheimer's disease), mostly affecting the memory domain.[7] However, most people (~75%) beyond age 85 have some Alzheimer's disease-type pathology and in this common scenario the impact of LATE-NC is very important.[8] Approximately one-half of persons with Alzheimer's disease pathology also have LATE-NC.[9] [10] [11] In these persons, the presence of LATE-NC is associated with a swifter disease course and with more severe clinical (memory and thinking) impairment than when only Alzheimer's disease pathology is present.[12] [13] [14] A common combination of brain pathologies—with Alzheimer's disease pathology, Lewy body pathology, and LATE-NC in the same brain—tends to affect younger individuals (often <75 yrs of age) and, on average, is associated with more aggressive (faster) cognitive deterioration.[5] [15] [12] With or without co-existing Alzheimer's disease pathology or other brain changes, persons with LATE-NC generally lack the clinical features of frontotemporal dementia (FTD).[16] [17]

For reasons that are presently unknown, the disease process of LATE-NC preferentially affects medial temporal lobe structures of the brain, particularly the amygdala and hippocampus.[18] In a significant proportion of persons with LATE-NC, there is atrophy, cell loss and astrogliosis in the hippocampus, diagnosable at autopsy (and somewhat less specifically via MRI during life) as hippocampal sclerosis.[19] Brains with LATE-NC and hippocampal sclerosis are relatively more affected clinically than those with LATE-NC alone.[20]

Signs and symptoms

Cognitive symptoms

The hallmark symptom of LATE is a progressive memory loss that predominantly affects short-term and episodic memory. This impairment is often severe enough to interfere with daily functioning and usually remains the chief neurologic deficit, unlike other types of dementia in which non-memory cognitive domains and behavioral changes might be noted earlier or more prominently. The amnestic syndrome in LATE tends to worsen gradually, leading to significant memory deficits and functional disabiltiy over time.[21] [22] [23]   Thus, the cognitive decline in LATE, when it is the chief pathology present, is typically relatively slow.[24]

The term dementia refers to a clinical syndrome, rather than a particular disease process – it can be caused by many different subtypes of brain disease, which often occur in combination with each other.  Thus, many different diseases including LATE contribute to dementia. The implications of the term dementia are that there is cognitive impairment severe enough to impair activities of daily living such as feeding oneself.[25] Approximately half of dementia in advanced age includes both Alzheimer's disease and LATE pathologies, and these individuals are at risk for more swift and severe disease course.[2][26] [27]

Causes

The exact causes of LATE are not fully understood, but a combination of factors, particularly genetic risk factors, are believed to contribute to its development. Here we explore these factors based on current research and theories.

Risk factors

The strongest known risk factor for LATE is advanced age. The prevalence of LATE increases significantly in individuals over 80 years old and the average patient with LATE is ten years older than the average patient with Alzheimer's disease, suggesting that aging-related biological processes—yet to be comprehensively identified (but which include TMEM106B C-terminal fragments[28] [29])—play roles in the development of LATE. Although brain trauma (either single or multiple/chronic traumatic impacts) can produce brain changes that are qualitatively different from LATE-NC[30] there may be interactions between brain trauma and LATE-NC mechanistically.  Further, those with brain damage from trauma or other sources may have worse outcomes with a given burden of LATE-NC in the brain. There is indication from broader dementia research that higher educational attainment and engaging in mentally stimulating activities might delay the onset of clinical symptoms in neurodegenerative diseases. Whether this directly affects the risk of developing LATE or just modifies its presentation is still under investigation. While specific lifestyle factors directly causing LATE have not been definitively identified, general factors that affect brain health appear to influence risk of a given amount of pathology being correlated with cognitive impairment.[31] Lifestyle factors that influence susceptibility to dementia include diet, physical activity, social and intellectual stimulation, cardiovascular health, and exposure to toxins. These may impair cognition in reciprocal relation to cognitive reserve.[32] Chronic inflammation in the brain is a known factor in many neurodegenerative diseases and may also play a role in LATE. Inflammatory processes could contribute to or exacerbate TDP-43 pathology.[33] Disruptions in protein homeostasis, which include protein synthesis, post-translational modification, folding, trafficking, and degradation, are likely involved in promoting TDP-43 pathology in LATE.[34] An imbalance in these processes could lead to the accumulation of misfolded TDP-43, contributing to disease progression.[35]

Genetic factors

The major known risk factors for LATE-NC are genetic: variations in the TMEM106B, GRN, APOE, ABCC9, KCNMB2, and WWOX genes have been linked to altered risk for LATE-NC (and/or hippocampal sclerosis dementia).[36] [37] [38] [39] [40] [41] [42] These genetic elements are associated with biochemical changes that affect the stability, aggregation propensity, or cellular trafficking of TDP-43. For example, the APOE e4 allele that confers increased risk for ADNC also increases risk of LATE-NC; it is also remarkable that FTLD risk genes TMEM106B and GRN/progranulin are also implicated in risk of LATE-NC.

Pathophysiology

TDP-43 (Transactive response DNA-binding protein) is a nuclear protein involved in regulating gene expression by modifying RNA.[43] More specifically, TDP-43plays critical roles in RNA processing, including splicing, stability, and transport. In healthy cells, TDP-43 is predominantly found in the nucleus. In LATE, TDP-43 protein abnormally accumulates in the cytoplasm of neurons and glial cells, forming aggregates. This cellular mis-localization disrupts its normal nuclear functions and contributes to cellular dysfunction and neuronal death. The exact triggers of TDP-43 aggregation are not fully understood but are believed to involve both genetic predispositions and acquired factors.[44] In normal brains and other tissues, the TDP-43 protein helps to ensure proper functioning of genes in the cell; the misfolded TDP-43 may thus impair normal gene expression regulation (so in LATE-NC, there is a loss-of-normal-function), and, the aberrant TDP-43 protein in LATE-NC may induce toxic gains of function also.[45] [46]

LATE neuropathology is typically graded based on the extent and distribution of TDP-43 inclusions within the brain. Early stages may involve localized TDP-43 pathology in the amygdala, while more advanced stages involve the hippocampus and other medial temporal lobe structures, whereas in more advanced disease the TDP-43 pathology is far more extensive. For more details on the pathological stages of LATE-NC, see “Pathologic Examination”, below.

Advanced LATE is often associated with hippocampal sclerosis,[47] characterized by severe neuron loss and gliosis in the hippocampus.[48] This feature significantly contributes to the memory deficits observed in LATE.[49] LATE often coexists with a small blood vessel pathology affecting cerebral arterioles, which is termed arteriolosclerosis.[50] LATE is more common in cases with comorbid tauopathy, including Alzheimer's-type plaques and tangles, primary age-related tauopathy (PART), and age-related tau astrogliopathy.

Diagnosis

The diagnosis of LATE is challenging because its symptoms overlap with those of other types of dementia, especially Alzheimer's disease, and there are no specific biomarkers to predict the presence of the pathology.[51] Thus, at present LATE is primarily diagnosed at autopsy, i.e., through neuropathological examination. However, ongoing research aims to refine the antemortem diagnostic criteria and methods. The current approach to diagnosing LATE in living patients involves a combination of clinical evaluation, neuroimaging, and biomarker analysis, as detailed below.

Clinical evaluation

Detailed patient history focusing on age at onset and nature and rate of decline of cognitive functions, particularly memory loss, is critical.[52] Clinicians also assess other cognitive domains and inquire about any changes in behavior or personality that might indicate broader neurological impact. Neuropsychologic examinations include testing to assess memory, executive function, language abilities, and other cognitive functions. These tests help differentiate LATE from other neurodegenerative diseases based on the presence of primarily amnestic versus multi-domain cognitive impairments.MRI scans are used to observe structural changes in the brain. In LATE, MRI may reveal severe atrophy in the medial temporal lobe, particularly in the hippocampus and amygdala, which are key areas affected by TDP-43 pathology, and may indicate hippocampal sclerosis.[53] Other MRI abnormalities have recently been also observed in association with LATE.[54] While PET scans are commonly used to detect amyloid and tau pathologies in Alzheimer's disease, the absence of marked aberration in these may support the diagnosis of LATE by ruling out significant amyloid or tau burdens indicative of Alzheimer's disease. FDG-PET scans may also be used to predict the presence of an underlying LATE-NC pathology.[55] [56]

Biomarkers for neuronal damage such as tau protein and neurofilaments can be measured in the cerebrospinal fluid and blood. A lack of amyloid-beta and tau relative to the degree of cognitive impairment may suggest LATE, if typical Alzheimer's pathology is not present. Vigorous efforts are ongoing to identify specific biomarkers for TDP-43 pathology.[57] These include potential CSF markers or blood-based biomarkers derived from advanced protein assays, which could specifically indicate the presence of abnormal TDP-43.

Pathological examination[edit]

Definitive diagnosis of LATE currently relies on post-mortem examination, in which brain tissues are examined for a specific pattern of TDP-43 proteinopathy. The distribution and severity of TDP-43 inclusions, especially in the amygdala and hippocampus (but with none or modest density of pathology in the frontal cortex), confirm the presence of LATE. The specific severity/extent of LATE-NC follows on the basic staging scheme based on a stereotypic expansion of TDP-43 pathology in the aged brain. This pattern was originally identified Keith Josephs and colleagues,[58] and was later corroborated by Dr. Julie Schneider and colleagues at Rush University Medical Center.[59]  For routine LATE-NC diagnosis, the pathology is staged along a 0-3 staging scheme: when TDP-43 pathology is only seen in the amygdala, that is LATE-NC Stage 1; when TDP-43 pathology is in the amygdala and hippocampus, that is LATE-NC Stage 2; and, when TDP-43 pathology is in amygdala, hippocampus, and middle frontal gyrus, that is LATE-NC Stage 3.[60]

Prognosis

The prognosis of LATE varies significantly depending on several factors including the age at onset, stage of the disease at diagnosis, the presence and degree of cerebrovascular disease and of other comorbidities, and individual patient factors.[61] Understanding the progression, expected outcomes, and influencing factors is crucial for managing LATE effectively and providing appropriate care and support to affected individuals and their families.

LATE typically manifests as a slow, progressive decline in memory and other cognitive functions, which distinguishes it from more rapidly progressing forms of dementia. The rate of progression can vary widely among individuals. Early stages may involve subtle memory impairments that gradually worsen. As LATE progresses, patients may experience more significant memory loss and eventually exhibit symptoms affecting other cognitive domains, although the primary impairment usually remains in memory. Progression to severe dementia is common, and as with many forms of dementia, individuals with LATE gradually require more assistance with daily activities, leading to significant dependency on caregivers.

Epidemiology

LATE is an increasingly recognized neurodegenerative condition and LATE neuropathological changes are present in >30% of individuals older than 85 years, making it one of the more common dementia-associated conditions in the elderly. LATE often coexists with other common brain pathologies of aging, such as Alzheimer's disease and/or cerebrovascular disorder. The risk of developing LATE increases with age,[62] being unusual in individuals under 65 and increasingly common in those over 80. Studies have not shown consistent differences between males and females in the prevalence of LATE. Several high-quality autopsy cohorts evaluating the "oldest-old" (>90yrs at death) have found that the correlative impact of LATE-NC on dementia rivals or exceeds that of Alzheimer's pathology in that age group.[63] [64] Limited data are available on the prevalence of LATE across different ethnic and racial groups. Initial studies have not indicated significant differences in prevalence based on race or ethnicity.[65] [66] [67] However, LATE has been identified in all the populations for which it has been evaluated, in studies around the world.[68] However, differences in study designs, diagnostic criteria, and awareness of the disease may affect reported rates from different countries. The recognition and reporting of LATE may also vary significantly depending on the local healthcare system's capacity to diagnose and record cases of dementia, particularly in settings where detailed neuropathological examinations are less common. Understanding the true epidemiological impact of LATE is essential for planning of research, healthcare, and resource allocation, especially as populations age.

History

The pathological signatures of the disorder now known as LATE have been observed at least since the mid-1990s, but attention on the TDP-43 protein that is part of its mechanism have been relatively recent.

The phenomenon of hippocampal sclerosis-linked dementia, as well as the link to TDP-43, were first described by Dr. Dennis Dickson and colleagues,[69] and this clinical-pathologic entity was subsequently confirmed by many others.[70] [71] [72] [73] [74] However, brain changes diagnosable as "hippocampal sclerosis" is/are also seen in other diseases (such as epilepsy), and many LATE-NC brains lack full-blown hippocampal sclerosis, so, hippocampal sclerosis is neither a sensitive nor specific feature of LATE-NC. TDP-43 proteinopathy itself (a disease-associated phenomenon discovered by Dr. Manuela Neumann and colleagues at UPENN in the Drs John Trojanowski/Virginia Lee CNDR Lab[75]) is also implicated in frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and other diseases.[76] [77]

It was not until the late 2000s and early 2010s that researchers began to recognize a pattern of TDP-43 pathology that was distinct from ALS and FTLD in elderly individuals, often co-existing with but distinct from Alzheimer's disease pathology.[78] A milestone in the history of LATE was the publication of a consensus report in 2019 by an international group of experts. This report formally recognized LATE as a distinct disease entity, described its neuropathological criteria, and provided a consensus description of clinical relevance. Thus, LATE was distinguished from other memory disorders of aging, and from other TDP-43 proteinopathies, and provided a universal terminology as required to facilitate communication (and raise awareness) among clinicians and researchers.  There has been some debate and discussion as to optimal nomenclature for this condition.[79] [80]

Further reading

Notes and References

  1. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, Coyle-Gilchrist IT, Chui HC, Fardo DW, Flanagan ME, Halliday G, Hokkanen SR, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GG, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murayama S, Murray ME, Nag S, Rissman RA, Seeley WW, Sperling RA, White CL, Yu L, Schneider JA . Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report . Brain . 142 . 6 . 1503–1527 . June 2019 . 31039256 . 6536849 . 10.1093/brain/awz099 .
  2. Nelson PT, Brayne C, Flanagan ME, Abner EL, Agrawal S, Attems J, Castellani RJ, Corrada MM, Cykowski MD, Di J, Dickson DW, Dugger BN, Ervin JF, Fleming J, Graff-Radford J, Grinberg LT, Hokkanen SR, Hunter S, Kapasi A, Kawas CH, Keage HA, Keene CD, Kero M, Knopman DS, Kouri N, Kovacs GG, Labuzan SA, Larson EB, Latimer CS, Leite RE, Matchett BJ, Matthews FE, Merrick R, Montine TJ, Murray ME, Myllykangas L, Nag S, Nelson RS, Neltner JH, Nguyen AT, Petersen RC, Polvikoski T, Reichard RR, Rodriguez RD, Suemoto CK, Wang SJ, Wharton SB, White L, Schneider JA . Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts . Acta Neuropathologica . 144 . 1 . 27–44 . July 2022 . 35697880 . 9552938 . 10.1007/s00401-022-02444-1 . 249628141 .
  3. Nichols E, Merrick R, Hay SI, Himali D, Himali JJ, Hunter S, Keage HA, Latimer CS, Scott MR, Steinmetz JD, Walker JM, Wharton SB, Wiedner CD, Crane PK, Keene CD, Launer LJ, Matthews FE, Schneider J, Seshadri S, White L, Brayne C, Vos T . The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia . The Lancet. Healthy Longevity . 4 . 3 . e115–e125 . March 2023 . 36870337 . 9977689 . 10.1016/S2666-7568(23)00019-3 .
  4. Harrison WT, Lusk JB, Liu B, Ervin JF, Johnson KG, Green CL, Wang SJ . Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) is independently associated with dementia and strongly associated with arteriolosclerosis in the oldest-old . Acta Neuropathologica . 142 . 5 . 917–919 . November 2021 . 34415381 . 8816525 . 10.1007/s00401-021-02360-w .
  5. Wang SJ, Guo Y, Ervin JF, Lusk JB, Luo S . Neuropathological associations of limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) differ between the oldest-old and younger-old . Acta Neuropathologica . 144 . 1 . 45–57 . July 2022 . 35551470 . 9997084 . 10.1007/s00401-022-02432-5 . 248701133 .
  6. Tomé SO, Gawor K, Thal DR . LATE-NC in Alzheimer's disease: Molecular aspects and synergies . Brain Pathology . 34 . 4 . e13213 . July 2024 . 37793659 . 11189776 . 10.1111/bpa.13213 .
  7. Nag S, Yu L, Wilson RS, Chen EY, Bennett DA, Schneider JA . TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD . Neurology . 88 . 7 . 653–660 . February 2017 . 28087828 . 5317379 . 10.1212/WNL.0000000000003610 .
  8. Braak H, Thal DR, Ghebremedhin E, Del Tredici K . Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years . Journal of Neuropathology and Experimental Neurology . 70 . 11 . 960–969 . November 2011 . 22002422 . 10.1097/NEN.0b013e318232a379 . 739734 . free .
  9. Buciuc M, Wennberg AM, Weigand SD, Murray ME, Senjem ML, Spychalla AJ, Boeve BF, Knopman DS, Jack CR, Kantarci K, Parisi JE, Dickson DW, Petersen RC, Whitwell JL, Josephs KA . Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes . Journal of Alzheimer's Disease . 73 . 4 . 1511–1523 . 2020 . 31929165 . 7081101 . 10.3233/JAD-191040 .
  10. Nag S, Barnes LL, Yu L, Wilson RS, Bennett DA, Schneider JA . Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents . Neurology . 95 . 15 . e2056–e2064 . October 2020 . 32759188 . 7713750 . 10.1212/WNL.0000000000010602 .
  11. Hunter S, Hokkanen SR, Keage HA, Fleming J, Minett T, Polvikoski T, Allinson K, Brayne C . TDP-43 Related Neuropathologies and Phosphorylation State: Associations with Age and Clinical Dementia in the Cambridge City over-75s Cohort . Journal of Alzheimer's Disease . 75 . 1 . 337–350 . 2020 . 32280087 . 10.3233/JAD-191093 . 215748586 .
  12. Karanth S, Nelson PT, Katsumata Y, Kryscio RJ, Schmitt FA, Fardo DW, Cykowski MD, Jicha GA, Van Eldik LJ, Abner EL . Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults . JAMA Neurology . 77 . 10 . 1299–1307 . October 2020 . 32568358 . 7309572 . 10.1001/jamaneurol.2020.1741 .
  13. Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM, Petrucelli L, Senjem ML, Ivnik RJ, Parisi JE, Petersen RC, Dickson DW . TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features . Annals of Neurology . 78 . 5 . 697–709 . November 2015 . 26224156 . 4623932 . 10.1002/ana.24493 .
  14. Josephs KA, Dickson DW, Tosakulwong N, Weigand SD, Murray ME, Petrucelli L, Liesinger AM, Senjem ML, Spychalla AJ, Knopman DS, Parisi JE, Petersen RC, Jack CR, Whitwell JL . Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study . The Lancet. Neurology . 16 . 11 . 917–924 . November 2017 . 28919059 . 5646369 . 10.1016/S1474-4422(17)30284-3 .
  15. Katsumata Y, Abner EL, Karanth S, Teylan MA, Mock CN, Cykowski MD, Lee EB, Boehme KL, Mukherjee S, Kauwe JS, Kryscio RJ, Schmitt FA, Fardo DW, Nelson PT . Distinct clinicopathologic clusters of persons with TDP-43 proteinopathy . Acta Neuropathologica . 140 . 5 . 659–674 . November 2020 . 32797255 . 7572241 . 10.1007/s00401-020-02211-0 .
  16. Nelson PT . LATE Neuropathologic Changes with Little or No Alzheimer Disease is Common and is Associated with Cognitive Impairment but Not Frontotemporal Dementia . Journal of Neuropathology and Experimental Neurology . 80 . 7 . 649–651 . August 2021 . 34270750 . 8357339 . 10.1093/jnen/nlab050 .
  17. Amador-Ortiz C, Ahmed Z, Zehr C, Dickson DW . Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration . Acta Neuropathologica . 113 . 3 . 245–252 . March 2007 . 17195931 . 1794627 . 10.1007/s00401-006-0183-4 .
  18. Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, Liesinger AM, Petersen RC, Parisi JE, Dickson DW . Updated TDP-43 in Alzheimer's disease staging scheme . Acta Neuropathologica . 131 . 4 . 571–585 . April 2016 . 26810071 . 5946692 . 10.1007/s00401-016-1537-1 .
  19. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW . TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease . Annals of Neurology . 61 . 5 . 435–445 . May 2007 . 17469117 . 2677204 . 10.1002/ana.21154 .
  20. Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, Davis DG, Poduska JW, Patel E, Mendiondo MS, Markesbery WR . Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons . Brain Pathology . 20 . 1 . 66–79 . January 2010 . 19021630 . 2864342 . 10.1111/j.1750-3639.2008.00244.x .
  21. Buciuc M, Tosakulwong N, Machulda MM, Whitwell JL, Weigand SD, Murray ME, Reichard RR, Parisi JE, Dickson DW, Boeve BF, Knopman DS, Petersen RC, Josephs KA . TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death . Journal of Alzheimer's Disease . 80 . 2 . 683–693 . 2021 . 33579840 . 8020877 . 10.3233/JAD-201166 .
  22. Farfel JM, Capuano AW, Buchman AS, Schneider JA, Bennett DA . Association of Alzheimer's Disease and Other Neuropathologies with Functional Disability in Persons With and Without Dementia . The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences . glae118 . May 2024 . 38757945 . 10.1093/gerona/glae118 .
  23. Leiby AC, Scambray KA, Nguyen HL, Basith F, Fakhraee S, Melikyan ZA, Bukhari SA, Montine TJ, Corrada MM, Kawas CH, Sajjadi SA . Characterizing Limbic-Predominant Age-Related TDP-43 Encephalopathy Without Alzheimer's Disease and Lewy Body Dementia in the Oldest Old: A Case Series . Journal of Alzheimer's Disease . 96 . 1 . 113–124 . 2023 . 37742640 . 10615772 . 10.3233/JAD-230238 .
  24. Kapasi A, Yu L, Boyle PA, Barnes LL, Bennett DA, Schneider JA . Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging . Neurology . 95 . 14 . e1951–e1962 . October 2020 . 32753441 . 7682843 . 10.1212/WNL.0000000000010454 .
  25. Mesulam MM . Dementia: its definition, differential diagnosis, and subtypes . JAMA . 253 . 17 . 2559–2561 . May 1985 . 3981786 . 10.1001/jama.1985.03350410125033 .
  26. Hamilton CA, Matthews FE, Attems J, Donaghy PC, Erskine D, Taylor JP, Thomas AJ . Associations between multimorbidity and neuropathology in dementia: consideration of functional cognitive disorders, psychiatric illness and dementia mimics . The British Journal of Psychiatry . 224 . 6 . 237–244 . June 2024 . 38584319 . 7615979 . 10.1192/bjp.2024.25 .
  27. Hiya S, Maldonado-Díaz C, Walker JM, Richardson TE . Cognitive symptoms progress with limbic-predominant age-related TDP-43 encephalopathy stage and co-occurrence with Alzheimer disease . Journal of Neuropathology and Experimental Neurology . 83 . 1 . 2–10 . December 2023 . 37966908 . 10746699 . 10.1093/jnen/nlad098 .
  28. Neumann M, Perneel J, Cheung S, Van den Broeck M, Nygaard H, Hsiung GR, Wynants S, Heeman B, Rademakers R, Mackenzie IR . Limbic-predominant age-related TDP-43 proteinopathy (LATE-NC) is associated with abundant TMEM106B pathology . Acta Neuropathologica . 146 . 1 . 163–166 . July 2023 . 37171635 . 10.1007/s00401-023-02580-2 .
  29. Riordan R, Saxton A, McMillan PJ, Kow RL, Liachko NF, Kraemer BC . TMEM106B C-terminal fragments aggregate and drive neurodegenerative proteinopathy . bioRxiv . 2024.06.11.598478 . June 2024 . 38915598 . 11195232 . 10.1101/2024.06.11.598478 .
  30. Nicks R, Clement NF, Alvarez VE, Tripodis Y, Baucom ZH, Huber BR, Mez J, Alosco ML, Aytan N, Cherry JD, Cormier KA, Kubilius C, Mathias R, Svirsky SE, Pothast MJ, Hildebrandt AM, Chung J, Han X, Crary JF, McKee AC, Frosch MP, Stein TD . Repetitive head impacts and chronic traumatic encephalopathy are associated with TDP-43 inclusions and hippocampal sclerosis . Acta Neuropathologica . 145 . 4 . 395–408 . April 2023 . 36681782 . 10.1007/s00401-023-02539-3 .
  31. 2023 Alzheimer's disease facts and figures . Alzheimer's & Dementia . 19 . 4 . 1598–1695 . April 2023 . 36918389 . 10.1002/alz.13016 .
  32. Pinto JO, Peixoto B, Dores AR, Barbosa F . Measures of cognitive reserve: An umbrella review . The Clinical Neuropsychologist . 38 . 1 . 42–115 . January 2024 . 37073431 . 10.1080/13854046.2023.2200978 .
  33. Kapasi A, Yu L, Leurgans SE, Agrawal S, Boyle PA, Bennett DA, Schneider JA . Association between hippocampal microglia, AD and LATE-NC, and cognitive decline in older adults . Alzheimer's & Dementia . 20 . 5 . 3193–3202 . May 2024 . 38494787 . 11095444 . 10.1002/alz.13780 .
  34. Keating SS, San Gil R, Swanson ME, Scotter EL, Walker AK . TDP-43 pathology: From noxious assembly to therapeutic removal . Progress in Neurobiology . 211 . 102229 . April 2022 . 35101542 . 10.1016/j.pneurobio.2022.102229 .
  35. Cheng F, Chapman T, Zhang S, Morsch M, Chung R, Lee A, Rayner SL . Understanding age-related pathologic changes in TDP-43 functions and the consequence on RNA splicing and signalling in health and disease . Ageing Research Reviews . 96 . 102246 . April 2024 . 38401571 . 10.1016/j.arr.2024.102246 . free .
  36. Dickson DW, Baker M, Rademakers R . Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly . Neuro-Degenerative Diseases . 7 . 1–3 . 170–174 . 2010 . 20197700 . 2859236 . 10.1159/000289231 .
  37. Murray ME, Cannon A, Graff-Radford NR, Liesinger AM, Rutherford NJ, Ross OA, Duara R, Carrasquillo MM, Rademakers R, Dickson DW . Differential clinicopathologic and genetic features of late-onset amnestic dementias . Acta Neuropathologica . 128 . 3 . 411–421 . September 2014 . 24899141 . 4412022 . 10.1007/s00401-014-1302-2 .
  38. Nelson PT, Estus S, Abner EL, Parikh I, Malik M, Neltner JH, Ighodaro E, Wang WX, Wilfred BR, Wang LS, Kukull WA, Nandakumar K, Farman ML, Poon WW, Corrada MM, Kawas CH, Cribbs DH, Bennett DA, Schneider JA, Larson EB, Crane PK, Valladares O, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, Scheff SW, Sonnen JA, Haines JL, Pericak-Vance MA, Mayeux R, Farrer LA, Van Eldik LJ, Horbinski C, Green RC, Gearing M, Poon LW, Kramer PL, Woltjer RL, Montine TJ, Partch AB, Rajic AJ, Richmire K, Monsell SE, Schellenberg GD, Fardo DW . ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology . Acta Neuropathologica . 127 . 6 . 825–843 . 2014 . 24770881 . 4113197 . 10.1007/s00401-014-1282-2 .
  39. Dugan AJ, Nelson PT, Katsumata Y, Shade LM, Boehme KL, Teylan MA, Cykowski MD, Mukherjee S, Kauwe JS, Hohman TJ, Schneider JA, Fardo DW . Analysis of genes (TMEM106B, GRN, ABCC9, KCNMB2, and APOE) implicated in risk for LATE-NC and hippocampal sclerosis provides pathogenetic insights: a retrospective genetic association study . Acta Neuropathologica Communications . 9 . 1 . 152 . September 2021 . 34526147 . 8442328 . 10.1186/s40478-021-01250-2 . free .
  40. Yang HS, Yu L, White CC, Chibnik LB, Chhatwal JP, Sperling RA, Bennett DA, Schneider JA, De Jager PL . Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study . The Lancet. Neurology . 17 . 9 . 773–781 . September 2018 . 30093249 . 6154505 . 10.1016/S1474-4422(18)30251-5 .
  41. Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, Corneveaux JJ, Hardy J, Vonsattel JP, Younkin SG, Bennett DA, De Jager PL, Larson EB, Crane PK, Kamboh MI, Kofler JK, Mash DC, Duque L, Gilbert JR, Gwirtsman H, Buxbaum JD, Kramer P, Dickson DW, Farrer LA, Frosch MP, Ghetti B, Haines JL, Hyman BT, Kukull WA, Mayeux RP, Pericak-Vance MA, Schneider JA, Trojanowski JQ, Reiman EM, Schellenberg GD, Montine TJ . Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias . PLOS Genetics . 10 . 9 . e1004606 . September 2014 . 25188341 . 4154667 . 10.1371/journal.pgen.1004606 . free .
  42. Dugan AJ, Nelson PT, Katsumata Y, Shade LM, Teylan MA, Boehme KL, Mukherjee S, Kauwe JS, Hohman TJ, Schneider JA, Fardo DW . Association between WWOX/MAF variants and dementia-related neuropathologic endophenotypes . Neurobiology of Aging . 111 . 95–106 . March 2022 . 34852950 . 8761217 . 10.1016/j.neurobiolaging.2021.10.011 . 240120472 .
  43. Cheng F, Chapman T, Zhang S, Morsch M, Chung R, Lee A, Rayner SL . Understanding age-related pathologic changes in TDP-43 functions and the consequence on RNA splicing and signalling in health and disease . Ageing Research Reviews . 96 . 102246 . April 2024 . 38401571 . 10.1016/j.arr.2024.102246 . free .
  44. Nilaver BI, Urbanski HF . Mechanisms underlying TDP-43 pathology and neurodegeneration: An updated Mini-Review . Frontiers in Aging Neuroscience . 15 . 1142617 . 2023 . 36967829 . 10034072 . 10.3389/fnagi.2023.1142617 . free .
  45. Chen HJ, Mitchell JC . Mechanisms of TDP-43 Proteinopathy Onset and Propagation . International Journal of Molecular Sciences . 22 . 11 . 6004 . June 2021 . 34199367 . 8199531 . 10.3390/ijms22116004 . free .
  46. Gendron TF, Rademakers R, Petrucelli L . TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43 . Journal of Alzheimer's Disease . 33 Suppl 1 . Suppl 1 . S35–S45 . 2013 . 22751173 . 3532959 . 10.3233/JAD-2012-129036 .
  47. Book: Amador-Ortiz C, Dickson DW . Dementias . 2008 . Neuropathology of hippocampal sclerosis . https://pubmed.ncbi.nlm.nih.gov/18631779 . Handbook of Clinical Neurology . 89 . 569–572 . 10.1016/S0072-9752(07)01253-5 . 0072-9752 . 18631779. 978-0-444-51898-9 .
  48. Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E, Thomason PC, Neltner JH, Smith CD, Santacruz KS, Sonnen JA, Poon LW, Gearing M, Green RC, Woodard JL, Van Eldik LJ, Kryscio RJ . Hippocampal sclerosis in advanced age: clinical and pathological features . Brain . 134 . Pt 5 . 1506–1518 . May 2011 . 21596774 . 3097889 . 10.1093/brain/awr053 .
  49. Sordo L, Qian T, Bukhari SA, Nguyen KM, Woodworth DC, Head E, Kawas CH, Corrada MM, Montine TJ, Sajjadi SA . Characterization of hippocampal sclerosis of aging and its association with other neuropathologic changes and cognitive deficits in the oldest-old . Acta Neuropathologica . 146 . 3 . 415–432 . September 2023 . 37382680 . 10412485 . 10.1007/s00401-023-02606-9 .
  50. Neltner JH, Abner EL, Baker S, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, Hammack E, Kukull WA, Brenowitz WD, Van Eldik LJ, Nelson PT . Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing . Brain . 137 . Pt 1 . 255–267 . January 2014 . 24271328 . 3891448 . 10.1093/brain/awt318 .
  51. Duong MT, Wolk DA . Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers . Current Neurology and Neuroscience Reports . 22 . 11 . 689–698 . November 2022 . 36190653 . 9633415 . 10.1007/s11910-022-01232-4 .
  52. Nelson PT, Schneider JA, Jicha GA, Duong MT, Wolk DA . When Alzheimer's is LATE: Why Does it Matter? . Annals of Neurology . 94 . 2 . 211–222 . August 2023 . 37245084 . 10516307 . 10.1002/ana.26711 .
  53. Yu L, Boyle PA, Dawe RJ, Bennett DA, Arfanakis K, Schneider JA . Contribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons . Neurology . 94 . 2 . e142–e152 . January 2020 . 31757868 . 6988988 . 10.1212/WNL.0000000000008679 .
  54. Young AL, Vogel JW, Robinson JL, McMillan CT, Ossenkoppele R, Wolk DA, Irwin DJ, Elman L, Grossman M, Lee VM, Lee EB, Hansson O . Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies . Brain . 146 . 7 . 2975–2988 . July 2023 . 37150879 . 10317181 . 10.1093/brain/awad145 .
  55. Corriveau-Lecavalier N, Botha H, Graff-Radford J, Switzer AR, Przybelski SA, Wiste HJ, Murray ME, Reichard RR, Dickson DW, Nguyen AT, Ramanan VK, McCarter SJ, Boeve BF, Machulda MM, Fields JA, Stricker NH, Nelson PT, Grothe MJ, Knopman DS, Lowe VJ, Petersen RC, Jack CR, Jones DT . Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome . Brain Communications . 6 . 4 . fcae183 . 2024 . 39021510 . 11251771 . 10.1093/braincomms/fcae183 .
  56. Grothe MJ, Moscoso A, Silva-Rodríguez J, Lange C, Nho K, Saykin AJ, Nelson PT, Schöll M, Buchert R, Teipel S . Differential diagnosis of amnestic dementia patients based on an FDG-PET signature of autopsy-confirmed LATE-NC . Alzheimer's & Dementia . 19 . 4 . 1234–1244 . April 2023 . 35971593 . 9929029 . 10.1002/alz.12763 .
  57. López-Carbonero JI, García-Toledo I, Fernández-Hernández L, Bascuñana P, Gil-Moreno MJ, Matías-Guiu JA, Corrochano S . In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use . Translational Neurodegeneration . 13 . 1 . 29 . June 2024 . 38831349 . 11149336 . 10.1186/s40035-024-00419-8 . free .
  58. Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, Liesinger AM, Petersen RC, Parisi JE, Dickson DW . Updated TDP-43 in Alzheimer's disease staging scheme . Acta Neuropathologica . 131 . 4 . 571–585 . April 2016 . 26810071 . 5946692 . 10.1007/s00401-016-1537-1 .
  59. Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, Schneider JA . TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer's disease . Acta Neuropathologica Communications . 6 . 1 . 33 . May 2018 . 29716643 . 5928580 . 10.1186/s40478-018-0531-3 . free .
  60. Nelson PT, Lee EB, Cykowski MD, Alafuzoff I, Arfanakis K, Attems J, Brayne C, Corrada MM, Dugger BN, Flanagan ME, Ghetti B, Grinberg LT, Grossman M, Grothe MJ, Halliday GM, Hasegawa M, Hokkanen SR, Hunter S, Jellinger K, Kawas CH, Keene CD, Kouri N, Kovacs GG, Leverenz JB, Latimer CS, Mackenzie IR, Mao Q, McAleese KE, Merrick R, Montine TJ, Murray ME, Myllykangas L, Nag S, Neltner JH, Newell KL, Rissman RA, Saito Y, Sajjadi SA, Schwetye KE, Teich AF, Thal DR, Tomé SO, Troncoso JC, Wang SJ, White CL, Wisniewski T, Yang HS, Schneider JA, Dickson DW, Neumann M . LATE-NC staging in routine neuropathologic diagnosis: an update . Acta Neuropathologica . 145 . 2 . 159–173 . February 2023 . 36512061 . 9849315 . 10.1007/s00401-022-02524-2 .
  61. Nag S, Schneider JA . Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases . Nature Reviews. Neurology . 19 . 9 . 525–541 . September 2023 . 37563264 . 10964248 . 10.1038/s41582-023-00846-7 .
  62. Carlos AF, Tosakulwong N, Weigand SD, Boeve BF, Knopman DS, Petersen RC, Nguyen A, Reichard RR, Murray ME, Dickson DW, Josephs KA . July 2022 . Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia . Acta Neuropathologica . 144 . 1 . 159–160 . 10.1007/s00401-022-02434-3 . 9943023 . 35536384.
  63. Mikhailenko E, Colangelo K, Tuimala J, Kero M, Savola S, Raunio A, Kok EH, Tanskanen M, Mäkelä M, Puttonen H, Mäyränpää MI, Kumar D, Kaivola K, Paetau A, Tienari PJ, Polvikoski T, Myllykangas L . Limbic-predominant age-related TDP-43 encephalopathy in the oldest old: a population-based study . Brain . awae212 . June 2024 . 38938199 . 10.1093/brain/awae212 .
  64. Sajjadi SA, Bukhari S, Scambray KA, Yan R, Kawas C, Montine TJ, Corrada MM . Impact and Risk Factors of Limbic Predominant Age-Related TDP-43 Encephalopathy Neuropathologic Change in an Oldest-Old Cohort . Neurology . 100 . 2 . e203–e210 . January 2023 . 36302666 . 9841447 . 10.1212/WNL.0000000000201345 .
  65. Katsumata Y, Fardo DW, Shade LM, Nelson PT . LATE-NC risk alleles (in TMEM106B, GRN, and ABCC9 genes) among persons with African ancestry . Journal of Neuropathology and Experimental Neurology . 82 . 9 . 760–768 . August 2023 . 37528055 . 10440720 . 10.1093/jnen/nlad059 . Peter T. .
  66. Huie EZ, Escudero A, Saito N, Harvey D, Nguyen ML, Lucot KL, LaGrande J, Mungas D, DeCarli C, Lamar M, Schneider JA, Kapasi A, Rissman RA, Teich AF, Dugger BN . TDP-43 Pathology in the Setting of Intermediate and High Alzheimer's Disease Neuropathologic Changes: A Preliminary Evaluation Across Ethnoracial Groups . Journal of Alzheimer's Disease . 91 . 4 . 1291–1301 . 2023 . 36617779 . 9974776 . 10.3233/JAD-220558 .
  67. Gibson LL, Grinberg LT, Ffytche D, Leite RE, Rodriguez RD, Ferretti-Rebustini RE, Pasqualucci CA, Nitrini R, Jacob-Filho W, Aarsland D, Suemoto CK . Neuropathological correlates of neuropsychiatric symptoms in dementia . Alzheimer's & Dementia . 19 . 4 . 1372–1382 . April 2023 . 36150075 . 10033459 . 10.1002/alz.12765 .
  68. Nichols E, Merrick R, Hay SI, Himali D, Himali JJ, Hunter S, Keage HA, Latimer CS, Scott MR, Steinmetz JD, Walker JM, Wharton SB, Wiedner CD, Crane PK, Keene CD, Launer LJ, Matthews FE, Schneider J, Seshadri S, White L, Brayne C, Vos T . The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia . The Lancet. Healthy Longevity . 4 . 3 . e115–e125 . March 2023 . 36870337 . 9977689 . 10.1016/S2666-7568(23)00019-3 .
  69. Dickson DW, Davies P, Bevona C, Van Hoeven KH, Factor SM, Grober E, Aronson MK, Crystal HA . Hippocampal sclerosis: a common pathological feature of dementia in very old (> or = 80 years of age) humans . Acta Neuropathologica . 88 . 3 . 212–221 . 1994 . 7810292 . 10.1007/BF00293396 . 6265307 .
  70. Hokkanen SR, Hunter S, Polvikoski TM, Keage HA, Minett T, Matthews FE, Brayne C . Hippocampal sclerosis, hippocampal neuron loss patterns and TDP-43 in the aged population . Brain Pathology . 28 . 4 . 548–559 . July 2018 . 28833898 . 6099461 . 10.1111/bpa.12556 .
  71. Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, Hepker M, Hwang JH, Miller ZA, Huang EJ, Karydas AM, Grant H, Boxer AL, Gorno-Tempini ML, Rosen HJ, Kramer JH, Miller BL, Seeley WW, Rabinovici GD, Grinberg LT . Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease . Brain . 144 . 7 . 2186–2198 . August 2021 . 33693619 . 8502474 . 10.1093/brain/awab099 .
  72. Zarow C, Weiner MW, Ellis WG, Chui HC . Prevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample . Brain and Behavior . 2 . 4 . 435–442 . July 2012 . 22950047 . 3432966 . 10.1002/brb3.66 .
  73. Makkinejad N, Schneider JA, Yu J, Leurgans SE, Kotrotsou A, Evia AM, Bennett DA, Arfanakis K . Associations of amygdala volume and shape with transactive response DNA-binding protein 43 (TDP-43) pathology in a community cohort of older adults . Neurobiology of Aging . 77 . 104–111 . May 2019 . 30784812 . 6486844 . 10.1016/j.neurobiolaging.2019.01.022 .
  74. Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E, Thomason PC, Neltner JH, Smith CD, Santacruz KS, Sonnen JA, Poon LW, Gearing M, Green RC, Woodard JL, Van Eldik LJ, Kryscio RJ . Hippocampal sclerosis in advanced age: clinical and pathological features . Brain . 134 . Pt 5 . 1506–1518 . May 2011 . 21596774 . 3097889 . 10.1093/brain/awr053 .
  75. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM . Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis . Science . 314 . 5796 . 130–133 . October 2006 . 17023659 . 10.1126/science.1134108 . 2006Sci...314..130N . 8620103 .
  76. News: . 30 April 2019 . Newly recognized form of dementia could now be easier to diagnose . 30 April 2019 . New Scientist.
  77. Chornenkyy Y, Fardo DW, Nelson PT . Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy . Laboratory Investigation; A Journal of Technical Methods and Pathology . 99 . 7 . 993–1007 . July 2019 . 30742063 . 6609463 . 10.1038/s41374-019-0196-y .
  78. Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM, Petrucelli L, Senjem ML, Ivnik RJ, Parisi JE, Petersen RC, Dickson DW . TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features . Annals of Neurology . 78 . 5 . 697–709 . November 2015 . 26224156 . 4623932 . 10.1002/ana.24493 .
  79. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, Coyle-Gilchrist IT, Fardo DW, Flanagan ME, Halliday G, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GG, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murray ME, Nag S, Seeley WW, Sperling RA, White CL, Schneider JA . Reply: LATE to the PART-y . Brain . 142 . 9 . e48 . September 2019 . 31359039 . 6931389 . 10.1093/brain/awz226 .
  80. Josephs KA, Mackenzie I, Frosch MP, Bigio EH, Neumann M, Arai T, Dugger BN, Ghetti B, Grossman M, Hasegawa M, Herrup K, Holton J, Jellinger K, Lashley T, McAleese KE, Parisi JE, Revesz T, Saito Y, Vonsattel JP, Whitwell JL, Wisniewski T, Hu W . LATE to the PART-y . Brain . 142 . 9 . e47 . September 2019 . 31359030 . 6736234 . 10.1093/brain/awz224 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Limbic-predominant age-related TDP-43 encephalopathy".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.